By Developers of Oxford-AstraZeneca Vaccine Tied to UK Eugenics Movement
by Jeremy Loffredo and Whitney Webb | Unlimited Hangout
On April 30, AstraZeneca and the University of Oxford announced a “landmark agreement” for the development of a COVID-19 vaccine. The agreement involves AstraZeneca overseeing aspects of the development as well as manufacturing and distribution while the Oxford side, via the Jenner Institute and Oxford Vaccine Group, researched and developed the vaccine. Less than a month after this agreement was reached, the Oxford-AstraZeneca partnership was awarded a contract from the US government as part of Operation Warp Speed, the public-private COVID-19 vaccination effort dominated by the US military and US intelligence.
Though the partnership was announced in April, Oxford’s Jenner Institute had already begun developing the COVID-19 vaccine months before, in mid-January. According to a recent BBC report, it was in January that the Jenner Institute first became aware of how serious the pandemic would soon become, when Andrew Pollard, who works for the Jenner Institute and heads the Oxford Vaccine Group, “shared a taxi with a modeler who worked for the UK’s Scientific Advisory Group for Emergencies.” During the taxi ride, “the scientist told him data suggested there was going to be a pandemic not unlike the 1918 flu.” Because of this sole encounter, we are told, the Jenner Institute began to pour millions into the early development of a vaccine for COVID-19, well before the scope of the crisis was clear.
For much of 2020, the Oxford-AstraZeneca vaccine was treated as an early frontrunner, though its lead would later be marred by scandals related to its clinical trials, including the death of participants, sudden trial pauses, the use of a problematic “placebo” with its own host of side effects, and the “unintentional” misdosing of some participants that skewed its self-reported efficacy rate.
The significant issues that emerged during trials have provoked little concern from the vaccine’s two lead developers, despite critical attention from even mainstream media directed at its complications. The lead developer of the Oxford-AstraZeneca vaccine, Adrian Hill, told NBC on December 9 that the experimental vaccine should be approved and distributed to the public before the conclusion of the safety trials, saying “to wait for the end of the trial would be the middle of next year. That’s too late, this vaccine is effective, available at large scale and easily deployed.”
Sarah Gilbert, the other lead researcher on the vaccine, seemed to believe that premature safety approval was likely, telling the BBC on December 13 that the chances of rolling out the vaccine by the end of the year are “pretty high.” Now, the UK is expected to approve the Oxford-AstraZeneca vaccine shortly after Christmas, with India also set to approve the vaccine next week.
While the controversies surrounding the vaccine’s trials did ultimately undermine its previous frontrunner status, the Oxford-AstraZeneca vaccine remains heavily promoted as the vaccine of choice for the developing world, as it is cheaper and has much less complicated storage requirements than its main competitors, Pfizer and Moderna.
Earlier this month, Richard Horton, editor in chief of the Lancet medical journal, told CNBC that “the Oxford-AstraZeneca vaccine is the vaccine right now that is going to be able to immunize the planet more effectively, more rapidly than any other vaccine we have,” in large part because it is a “vaccine that can get to lower-middle-income countries.” CNBC also quoted Andrew Baum, global head of health care for Citi Group, as saying that the Oxford-AstraZeneca vaccine “is really the only vaccine that is going to suppress or even eradicate SARS-CoV-2, the virus that causes COVID-19, in the many millions of individuals in the developing world.”
In addition to longstanding claims that the Oxford-AstraZeneca vaccine will be the vaccine of choice for the developing world, this vaccine candidate has also been treated by several outlets in the mainstream, and even independent media, as “good for people, bad for profits” due to the partnership’s “explicit intention of supplying [the vaccine] around the world on a not-for-profit basis, meaning that the poorest nations on the planet will not have to worry about being shut out of a cure due to lack of funds.”
However, investigation into the vaccine’s developers and the realities of their “no-profit pledge” reveals a very different story than that which has been spun for most of the year by corporate press releases, experts, and academics tied to the vaccine and the mainstream press.
For instance, mainstream media has had little, if anything, to say about the role of the vaccine developers’ private company—Vaccitech—in the Oxford-AstraZeneca partnership, a company whose main investors include former top Deutsche Bank executives, Silicon Valley behemoth Google, and the UK government. All of them stand to profit from the vaccine alongside the vaccine’s two developers, Adrian Hill and Sarah Gilbert, who retain an estimated 10 percent stake in the company. Another overlooked point is the plan to dramatically alter the current sales model for the vaccine following the initial wave of its administration, which would see profits soar, especially if the now-obvious push to make COVID-19 vaccination an annual affair for the foreseeable future is made reality. Read Full Article >
